🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Taiwan / NCT05613621
Active, not recruiting Observational

Dissection of the Molecular and Immunological Interaction in Patients With HCC of Viral and Non-viral Etiologies

NCT05613621 · tracked via the Priya Life Science Taiwan tracker
Phase
Observational
Started
2025-08-14
Last updated
2025-08-15

Condition(s) studied

Hepatocellular Carcinoma

Study summary

This project will clarify the potential interaction between HBV infection and steatosis, and their impact on genetic alterations and tumor immune microenvironment.

Eligibility

Sex
ALL
Min age
20 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Adult female or male patients aged ≥20 years. 2. HCC has been histologically confirmed with resection specimen. 3. The surgery should be performed with curative intent after 2015 in the study hospital. 4. Availability of serum HBsAg and Anti-HBc data in the electronic medical record. 5. Availability of imaging data performed within 3 months before the surgery in the electronic medical record. (at least one of the following: computed tomography, magnetic resonance imaging, abdominal sonography). 6. Informed consent is obtained. Willingness to provide the residual operative slides and medical records. Exclusion Criteria: 1. Fibrolamellar HCC, sarcomatoid HCC, or a mixture of cholangiocarcinoma and HCC 2. Exclusion of HCV patients (Anti-HCV positive) 3. Inability to cooperate by providing a complete medical history.

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
National Cheng-Kung University Hospital Tainan Taiwan
National Taiwan University Hospital Taipei Taiwan
Mackay Memorial Hospital Taipei Taiwan
National Taiwan University Cancer Center Taipei Taiwan

More National Health Research Institutes, Taiwan trials in Taiwan

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05613621 on ClinicalTrials.gov ↗ ← All trials in Taiwan